Home

Content about Merck

02.23.10
Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

02.18.10
Gardasil Effective In Women Ages 25 To 45, Young Men, Merck Studies Show

Merck's human papillomavirus vaccine, Gardasil, effectively prevented precancerous cervical lesions and genital warts in women ages 24 through 45, and it prevented anal cancer and precancerous anal lesions in young men who have sex with men, according to two studies released by the company on Wednesday, the AP/Philadelphia Inquirer reports...

12.22.09
Former CDC head to lead Merck's vaccine division

The pharmaceutical company Merck on Monday named former CDC head Julie Gerberding as president of the company's vaccine division, Reuters reports. "Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia," the news service reports.

06.24.09
Merck Partners With Non-Profit For Neglected Diseases Initiative

The pharmaceutical company, Merck, announced Monday it was partnering with the non-profit Drugs for Neglected Diseases initiative (DNDi) in an effort to improve treatments for neglected tropical diseases (NTD), the AP/CNBC reports. "The agreement covers drug candidates for illnesses like visceral leishmaniasis and Chagas disease, potentially lethal parasitic illnesses spread by insects.